Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Biochemical Pharmacology|May 15, 2002
Recognition forces involved in mitochondrial binding to a low-affinity trimetazidine binding site related to anti-ischemic activityGeorgette Plemper van Balen, Pierre Alain Carrupt, Didier Morin, et al.
Pacing and Clinical Electrophysiology : PACE|November 26, 2009
Is surface ECG a useful surrogate for subcutaneous ECG?Carissa L Bellardine Black, Kurt Stromberg, Georgette Plemper van Balen, et al.
Medicinal Research Reviews|March 3, 2004
Liposome/water lipophilicity: methods, information content, and pharmaceutical applicationsGeorgette Plemper van Balen, Catherine a Marca Martinet, Giulia Caron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2011
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Jakko van Ingen, Rob E Aarnoutse, Peter R Donald, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
Pageof 1